MindMed announces successfully completing Phase I for 18-MC, with patients receiving dosages of up tp 325 mg.
In a groundbreaking decision, the Canadian government is changing the way patients can access psychedelic therapies with restricted drugs, including MDMA and psilocybin.
MindMed announces that the FDA has placed "clinical hold" on its initial IND submission in preparation for its Phase 2b clinical trial for generalized anxiety disorder (GAD).
In Part II, we take a personal look at the journey into PTSD Hell. We also examine the additional serious issues facing veterans attempting to cope with PTSD.
Cybin Inc provides a year-end update highlighting drug and IP development as well as international expansion.
Optimi Health receives its Health Canada Dealers' License and initiates new Quality Assurance Department.
2021 was two different "years" for the psychedelic drug industry. Impressive progress in drug R&D and clinics; stocks pushed down to absurdly lean multiples.
Awakn Life Sciences reports its Q3 for fiscal 2021. Highlights include key IP and clinic acquisitions, and the company's first revenues.